The Center of Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University is involved in various different aspects of developing, evaluating and applying novel quantitative image analysis, computer vision, signal processing, segmentation, multi-modal co-registration tools, pattern recognition, and machine learning tools for disease diagnosis, prognosis, and theragnosis in the context of breast, prostate, head and neck, and brain tumors as well as epilepsy and carotid plaque. Our group is also exploring the utility of these methods in studying correlations of disease markers across multiple scales, modalities, and functionalities -- from gene and protein expression to spectroscopy to digital pathology and to multi-parametric MRI.

Sign up for the CCIPD newsletter here!

Facebook Live Stream with Anant

Latest News:

Thu, 2021-06-24 15:25

CWRU acquired 105 patents in 2020, 15 of which came from the CCIPD!
Read more about the drivers of CWRU’s patent production here

Thu, 2021-06-24 15:01

Amir Reza Sadri & Amogh Hiremath received travel awards to MICCAI 2021 to present their accepted MICCAI papers titled "SPARTA: An Integrated Stability, Discriminability, and Sparsity based Radiomic Feature Selection Approach," and “Integrated Lung Deformation Atlas and 3D-CNN Characterization of Infiltrates LuMiRa for COVID-19 Prognosis," respectively. 

Since this year’s MICCAI conference will be a virtual event, the travel award will go towards conference registration and MICCAI society student membership.

Thu, 2021-06-24 13:21

US Representative Kathy Castor recognized the 175 inventors who will soon be inducted as the 2020 Fellows of the National Academy of Inventors. This list includes the Director of the Center for Computational Imaging and Personalized Diagnostics, Dr. Anant Madabhushi, as well as Dr. Scott Bruder, a Biomedical Engineering Professor at CWRU. 

See the full remarks here.

Wed, 2021-06-23 13:08

A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients with  stage 3 non-small cell lung cancer (NSCLC) may be able to predict who will benefit from treatment from those likely to progress despite therapy. 

In an interview with Physician’s Weekly, Dr. Khalid Jazieh of the Cleveland Clinic explains that the current medical procedure for stage 3 NSCLC is to treat patients with chemoradiation followed by durvalumab consolidation. This is the standard of care for everybody regardless of the potential of the patient not needing the...

Tue, 2021-06-22 06:20

Oral-cancer research spans two continents to predict patient outcomes, advise better treatments

Dr. Anant Madabhushi and the Center for Computational Imaging and Personalized Diagnostics are highlighted in the Spring/Summer issue of CWRU’s Think Magazine. Read the article here.